[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Other Articles
December 17, 1938


Author Affiliations


Dr. Scheman is Merriel Abbott Fellow in Orthopaedic Surgery, Michael Reese Hospital.

JAMA. 1938;111(25):2265-2268. doi:10.1001/jama.1938.02790510013003

The treatment of pseudohypertrophic muscular dystrophy has passed through many cycles, depending on the prevailing theory of pathogenesis. Each has had a short period of usefulness which ended when failure to produce enduring clinical improvement made it no longer tenable. At present the myodystrophic patient will probably pass through the entire gamut of therapy, beginning with the more recent forms and working backward as each in turn is discarded as ineffective.

For a time all interest centered on endocrinologie factors,1 and practically every gland was incriminated. The pineal and pituitary2 glands were particularly singled out by many workers, who pointed to a similarity of symptoms in diseases of these ductless glands to those found in the dystrophic patient.

In medical writings repeated emphasis is placed on a supposed disturbance in carbohydrate metabolism.3 These statements are based on chemical studies4 and on deductions drawn from the occurrence